We are live on ! Find out more
PHS

PFM Health Sciences Portfolio holdings

AUM $1.1B
1-Year Est. Return 57.92%
This Fund
S&P 500
This Quarter Est. Return
+2.29%
1 Year Est. Return
+57.92%
3 Year Est. Return
+183.93%
5 Year Est. Return
+283%
10 Year Est. Return
+2,507.28%
AUM
$1.1B
AUM Growth
+$93.7M
Cap. Flow
+$96.1M
Cap. Flow %
8.76%
Top 10 Hldgs %
40.44%
Holding
102
New
24
Increased
37
Reduced
19
Closed
19

Top Buys

Rank Stock Value
1
JAZZ icon
Jazz Pharmaceuticals
JAZZ
+$22.3M
2
ABT icon
Abbott
ABT
+$15.9M
3
NTRA icon
Natera
NTRA
+$12.9M
4
MDGL icon
Madrigal Pharmaceuticals
MDGL
+$12.8M
5
MMSI icon
Merit Medical Systems
MMSI
+$12.7M

Top Sells

Rank Stock Value
1
ADMA icon
ADMA Biologics
ADMA
+$23.2M
2
MDT icon
Medtronic
MDT
+$20.5M
3
MRK icon
Merck
MRK
+$19.8M
4
CNC icon
Centene
CNC
+$18.9M
5
UTHR icon
United Therapeutics
UTHR
+$13.9M

Sector Composition

Rank Sector Weight
1 Healthcare 85.1%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
MBX
76
MBX Biosciences
MBX
$2.76B
$2.15M 0.2%
71,894
-7,416
-9% -$252K
AMLX icon
77
Amylyx Pharmaceuticals
AMLX
$2B
$2.02M 0.18%
145,275
+10,726
+8% +$151K
CRBU icon
78
Caribou Biosciences
CRBU
$165M
$1.82M 0.17%
957,787
– –
GMED icon
79
Globus Medical
GMED
$10.3B
$1.46M 0.13%
+16,923
New +$1.52M
TECX
80
Tectonic Therapeutic
TECX
$602M
$1.43M 0.13%
46,129
+3,405
+8% +$83.8K
QURE icon
81
uniQure
QURE
$2.77B
$697K 0.06%
42,635
+3,136
+8% +$63.5K
RZLT icon
82
Rezolute
RZLT
$478M
$393K 0.04%
128,726
-77,539
-38% -$233K
ADMA icon
83
ADMA Biologics
ADMA
$1.96B
– –
-1,270,894
Closed -$23.2M
ALGN icon
84
Align Technology
ALGN
$12.5B
– –
-42,304
Closed -$6.61M
CNC icon
85
CALL
Centene
CNC
$33B
– –
-372,300
Closed -$15.3M
CVS icon
86
CVS Health
CVS
$140B
– –
-107,767
Closed -$8.55M
ELAN icon
87
Elanco Animal Health
ELAN
$12.9B
– –
-207,311
Closed -$4.69M
FTRE icon
88
Fortrea Holdings
FTRE
$1.7B
– –
-165,439
Closed -$2.85M
GILD icon
89
Gilead Sciences
GILD
$163B
– –
-71,018
Closed -$8.72M
IQV icon
90
IQVIA
IQV
$33.6B
– –
-37,852
Closed -$8.53M
IRON icon
91
Disc Medicine
IRON
$2.85B
– –
-11,002
Closed -$874K
ISRG icon
92
Intuitive Surgical
ISRG
$121B
– –
-15,410
Closed -$8.73M
MDT icon
93
Medtronic
MDT
$105B
– –
-213,796
Closed -$20.5M
MOH icon
94
Molina Healthcare
MOH
$11.7B
– –
-22,802
Closed -$3.96M
MRK icon
95
Merck
MRK
$317B
– –
-187,834
Closed -$19.8M
NPCE icon
96
Neuropace
NPCE
$509M
– –
-11,329
Closed -$175K
SNY icon
97
Sanofi
SNY
$105B
– –
-176,413
Closed -$8.55M
TFX icon
98
Teleflex
TFX
$5.98B
– –
-102,395
Closed -$12.5M
TMCI icon
99
Treace Medical Concepts
TMCI
$263M
– –
-50,000
Closed -$123K
UHS icon
100
Universal Health Services
UHS
$9.06B
– –
-57,409
Closed -$12.5M
1 2 3
4
5

Similar funds

DAM
Delta Asset Management Memphis, Tennessee $1.1B AUM 14.89% 1-Year Est. Return
MAM
Mark Asset Management New York $1.1B AUM 43.79% 1-Year Est. Return
CPRC
Consolidated Portfolio Review Corp Woodbury, New York $1.1B AUM 8.96% 1-Year Est. Return
LCM
Legato Capital Management San Francisco, California $1.1B AUM 61.65% 1-Year Est. Return
PRS
Pinkerton Retirement Specialists Coeur D Alene, Idaho $1.1B AUM 30.57% 1-Year Est. Return
DAM
DLD Asset Management New York $1.1B AUM 4.68% 1-Year Est. Return
KCM
Khrom Capital Management Miami Beach, Florida $1.09B AUM 14.82% 1-Year Est. Return
CF
Corebridge Financial Houston, Texas $1.09B AUM 1.85% 1-Year Est. Return

PFM Health Sciences's Q1 2026 Portfolio in Review

As of Q1 2026, PFM Health Sciences held 102 positions worth $1.1B, up 9.3% from $1B the previous quarter. Its ten largest holdings account for 40% of the portfolio.

PFM Health Sciences deployed $96.1M of net new capital in Q1 2026, opening 24 new positions and adding to 37 existing holdings. Its largest new stake was Abbott: 140,432 shares worth $14.4M.

By sector, the portfolio is most concentrated in Healthcare at 85% of assets, down from 97% a quarter earlier.

On the sell side, the largest reduction was Centene, an estimated $18.9M trimmed.

  • PFM Health Sciences's largest Q1 2026 buy was Abbott: 140,432 shares worth $14.4M.
  • PFM Health Sciences added most to Jazz Pharmaceuticals in Q1 2026, an estimated $22.3M increase.
  • PFM Health Sciences's biggest Q1 2026 reduction was Centene, cutting an estimated $18.9M.
  • PFM Health Sciences fully exited ADMA Biologics in Q1 2026, selling an estimated $23.2M.
  • PFM Health Sciences's ten largest holdings make up 40% of its $1.1B portfolio in Q1 2026.
  • PFM Health Sciences opened 24 new positions and closed 19 in Q1 2026.
  • PFM Health Sciences's portfolio value rose 9.3% quarter-over-quarter to $1.1B.

Based on PFM Health Sciences's 13F filing for Q1 2026, filed 15 May 2026.